^
    Apply
    Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (NCT02520063)
    Phase 1/2
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    12/27/2024
    Initiation :
    02/23/2019
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • letrozole • carotuximab IV (ENV-105)
    Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer (NCT05401110)
    Phase 1
    Karen Reckamp, MD, MS
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    09/15/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • carotuximab IV (ENV-105)
    Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC (NCT03181308)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    06/24/2020
    Initiation :
    11/09/2017
    Primary completion :
    07/22/2019
    Completion :
    07/22/2019
    EGFR • PD-L1 • ROS1 • ALK1
    |
    Opdivo (nivolumab) • carotuximab IV (ENV-105)
    A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (NCT01975519)
    Phase 2a
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    05/20/2020
    Initiation :
    12/10/2013
    Primary completion :
    03/11/2019
    Completion :
    03/11/2019
    ENG
    |
    pazopanib • carotuximab IV (ENV-105)
    Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC (NCT03780010)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    10/28/2019
    Initiation :
    09/01/2015
    Primary completion :
    06/01/2019
    Completion :
    06/01/2019
    ALK1
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • carotuximab IV (ENV-105)
    Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer (NCT01326481)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    03/18/2019
    Initiation :
    06/01/2011
    Primary completion :
    09/01/2014
    Completion :
    12/01/2014
    HER-2
    |
    HER-2 negative
    |
    capecitabine • carotuximab IV (ENV-105)
    Sorafenib and TRC105 in Hepatocellular Cancer (NCT01306058)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/23/2019
    Initiation :
    02/11/2011
    Primary completion :
    06/01/2016
    Completion :
    06/09/2017
    ENG
    |
    sorafenib • carotuximab IV (ENV-105)
    Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated (NCT01332721)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    12/05/2018
    Initiation :
    04/01/2011
    Primary completion :
    09/01/2012
    Completion :
    12/01/2013
    MUC16
    |
    Avastin (bevacizumab) • carotuximab IV (ENV-105)
    Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (NCT01727089)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/28/2018
    Initiation :
    11/01/2012
    Primary completion :
    08/08/2017
    Completion :
    08/08/2017
    IL2
    |
    Avastin (bevacizumab) • carotuximab IV (ENV-105)
    Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma (NCT01757652)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    10/07/2015
    Initiation :
    12/01/2012
    Primary completion :
    01/01/2100
    ENG
    |
    carotuximab IV (ENV-105)